About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Therapy Response in Glioblastoma Cells is Linked to Disease Prognosis

by Dr. Trupti Shirole on December 15, 2016 at 11:41 PM
Font : A-A+

 Therapy Response in Glioblastoma Cells is Linked to Disease Prognosis

Glioblastoma is a very aggressive tumor form and affected patients only survive for, on average, approximately a year after diagnosis. It is difficult to treat and has very poor prognosis.

Researchers believe that the difficulties in treating the disease is caused by cells in the tumors called glioma-initiating cells (GICs), a kind of stem cells that can start growing again, after treatment has been finished.

Advertisement


In a new study, published in the journal Cell Reports, scientists from Uppsala University show that a type of stem cell in the tumor is present in different states, with different response to drugs and radiation.

The results may open an avenue towards development of new treatment strategies designed to reverse therapy resistant cell states to more sensitive states.
Advertisement

The new results from Uppsala University show that a single tumor contained GICs in different states that are differently resistant to therapy. Cell states that were resistant to radiation were also resistant to drugs, and states that were resistant to one drugs tended to be resistant to most of the other tested drugs.

"Another interesting result was that the GICs did not fall into distinct response groups. Instead the difference in their response can best be described as a continuum of cells with different resistance levels. We also discovered a relationship between the resistance level and molecular characteristics of the tumor that are associated with disease prognosis. A resistant cell state of the GICs was linked to characteristics associated with poor prognosis and a sensitive cell state was linked to characteristics associated with better outcome", says Anna Segerman, who has led the study together with Bengt Westermark, Department of Immunology, Genetics and Pathology.

A new strategy to treat glioblastoma could be to target the intertumor heterogeneity, i.e. the presence in the same tumor of a mix of GICs that have different resistance levels and are linked to different prognoses.

"We hypothesize that the mix of GICs with different resistance levels is formed by a drift between the different cell states. With more knowledge about the mechanisms behind this it might be possible to develop new therapies that reprogram the GICs to render them more sensitive to radiation and drugs", says Bengt Westermark.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Surgical Treatment Reiki and Pranic Healing Glioblastoma Multiforme 

Most Popular on Medindia

Blood Pressure Calculator Sanatogen Vent Forte (Theophylline) Noscaphene (Noscapine) Blood - Sugar Chart Indian Medical Journals A-Z Drug Brands in India Accident and Trauma Care Drug - Food Interactions Turmeric Powder - Health Benefits, Uses & Side Effects
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Therapy Response in Glioblastoma Cells is Linked to Disease Prognosis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests